DB17708InvestigationalCell transplant therapies
SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy. It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target... It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.
- Code names
- BIVV003 · SAR445136
What you can answer from here — as of September 25, 2025
Which companies are running trials of SAR445136, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account